Table 2.

Serum concentrations of, 5α-androstane-3α,17β-diol glucuronide, sex steroid hormones and sex hormone binding globulin, before and after finasteride treatment, among treatment-compliant men in the Prostate Cancer Prevention Trial finasteride arm.

	N	Median [IQR1]	Mean (SD)
3-α-dG (ng/mL)2
Baseline	1247	5.7 [3.9,8.0]	6.8 (5.1)
Post-Treatment	1247	1.5 [1.0,2.1]	1.9 (1.7)
Absolute Difference3,4	1247	−4.1 [−6.1,−2.4]	−4.9 (4.7)
Absolute Difference, Baseline Adjusted3,4	1247	−5.2 [−5.6,−4.7]	−4.9 (1.5)
% Difference 3,5	1247	−73.8 [−81.5,−62.6]	−67.1 (32.6)
Testosterone (ng/dL)
Baseline	1246	361 [285,448]	381 (138)
Post-Treatment	1246	398 [316,496]	421 (157)
Absolute Difference3,4	1246	37.0 [−31.0,103.0]	39.9 (121.0)
Absolute Difference, Baseline Adjusted3,4	1246	29.6 [−33.6,96.4]	39.9 (116.5)
% Difference3,5	1246	10.1 [−8.1,31.7]	14.7 (36.1)
Free Testosterone (ng/dL)
Baseline	1246	8.4 [6.8,10.0]	8.7 (2.7)
Post-Treatment	1246	9.1 [7.3,10.9]	9.4 (3.0)
Absolute Difference3,4	1246	0.7 [−1.00.,2.2]	0.7 (2.7)
Absolute Difference, Baseline Adjusted3,4	1246	0.5 [−0.9,2.0]	0.7 (2.5)
% Difference 3,5	1246	7.5 [−10.4,29.4]	12.5 (36.8)
Estrone (pg/mL)
Baseline	1227	44.4 [35.8,55.2]	46.5 (15.6)
Post-Treatment	1227	49.2 [39.9,59.8]	51.8 (17.0)
Absolute Difference3,4	1227	4.7 [−3.3,13.2]	5.2 (15.2)
Absolute Difference, Baseline Adjusted3,4	1227	3.7 [−3.8,11.8]	5.2 (14.0)
% Difference3,5	1227	11.2 [−7.2,35.5]	16.5 (35.3)
Estradiol (pg/mL)
Baseline	1236	33.5 [26.7,40.5]	34.6 (11.7)
Post-Treatment	1236	35.6 [29.3,43.3]	37.4 (12.4)
Absolute Difference3,4	1236	2.6 [−3.4,8.1]	2.7 (11.5)
Absolute Difference, Baseline Adjusted3,4	1236	1.9 [−3.4,7.4]	2.7 (10.4)
% Difference3,5	1236	7.5 [−8.8,28.1]	11.7 (32.4)
Free Estradiol (pg/mL)
Baseline	1236	0.9 [0.7,1.1]	0.9 (0.3)
Post-Treatment	1236	0.9 [0.8,1.2]	1.0 (0.3)
Absolute Difference3,4	1236	0.0 [−0.1,0.2]	0.1 (0.3)
Absolute Difference, Baseline Adjusted3,4	1236	0.0 [ 0.1,0.2]	0.1 (0.3)
% Difference3,5	1236	5.3 [−10.7,26.1]	9.6 (31.8)
Sex Hormone Binding Globulin (nmol/L)
Baseline	1247	36.0 [28.0,45.7]	38.5 (16.2)
Post-Treatment	1247	38.3 [29.4,48.7]	40.8 (16.3)
Absolute Difference3,4	1247	2.0 [−2.7,6.8]	2.3 (10.4)
Absolute Difference, Baseline Adjusted3,4	1247	1.3 [−3.1,6.4]	2.3 (9.9)
% Difference 3,5	1247	6.0 [−7.1,20.4]	8.9 (25.7)

¹Inter-quartile range

²5α-androstane-3α,17β-diol glucuronide

³p<0.0001

⁴Post-treatment – baseline

⁵100 · (Post-treatment – baseline)/baseline